ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | NDAQ

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
HELLENIC DYNAMICS PLC Cultivates and supplies THC-dominant medical cannabis for the European pharmaceutical market.	United Kingdom	HELD
HEMOGENYX PHARMACEUTICALS PLC Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.	United Kingdom	HEMO
HEM Pharma Inc. Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.	South Korea	376270
Hemp Health Spolka Akcyjna A vertically integrated supplier of medical cannabis raw material for the Polish market.	Poland	HMP
Herantis Pharma Oyj Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.	Finland	HRTIS
HERON THERAPEUTICS, INC. /DE/ Develops and commercializes therapies for acute care and oncology to manage pain and nausea.	United States of America	HRTX
HIGH TECH PHARM CO.,LTD. Global manufacturer of carbapenem antibiotic APIs for regulated markets.	South Korea	106190
HIKMA Pharmaceuticals PLC Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.	United Kingdom	HIK
HISAMITSU PHARMACEUTICAL CO.,INC. A global leader in transdermal drug delivery systems for OTC and prescription pain relief.	Japan	4530
HLB Genex, Inc. Develops custom enzymes & microbiome solutions for diagnostics, nutrition, and cosmetic markets.	South Korea	187420